emodin has been researched along with Cholangiocarcinoma in 3 studies
Emodin: Purgative anthraquinone found in several plants, especially RHAMNUS PURSHIANA. It was formerly used as a laxative, but is now used mainly as a tool in toxicity studies.
emodin : A trihydroxyanthraquinone that is 9,10-anthraquinone which is substituted by hydroxy groups at positions 1, 3, and 8 and by a methyl group at position 6. It is present in the roots and barks of numerous plants (particularly rhubarb and buckthorn), moulds, and lichens. It is an active ingredient of various Chinese herbs.
Cholangiocarcinoma: A malignant tumor arising from the epithelium of the BILE DUCTS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Emodin, a tyrosine kinase inhibitor, effectively blocked tyrosine phosphorylation of p185(neu) overexpressed in cultured rat C611B cholangiocarcinoma (ChC) cells and in neu-transformed WB-F344 rat-liver epithelial stem-like cells (WBneu cells)." | 7.72 | Celecoxib acts in a cyclooxygenase-2-independent manner and in synergy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced Akt inactivation and increased activation of caspases-9 and -3. ( Lai, GH; Sirica, AE; Zhang, Z, 2003) |
| "Emodin, a tyrosine kinase inhibitor, effectively blocked tyrosine phosphorylation of p185(neu) overexpressed in cultured rat C611B cholangiocarcinoma (ChC) cells and in neu-transformed WB-F344 rat-liver epithelial stem-like cells (WBneu cells)." | 3.72 | Celecoxib acts in a cyclooxygenase-2-independent manner and in synergy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced Akt inactivation and increased activation of caspases-9 and -3. ( Lai, GH; Sirica, AE; Zhang, Z, 2003) |
| "Cholangiocarcinoma is a rare but highly malignant primary hepatobiliary cancer with a high rate of mortality." | 1.31 | Cyclooxygenase-2 and ERBB-2 in cholangiocarcinoma: potential therapeutic targets. ( Endo, K; Lai, GH; Sirica, AE; Yoon, BI; Zhang, Z, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, X | 1 |
| Zhang, W | 1 |
| Jia, Y | 1 |
| Xu, H | 1 |
| Zhu, Y | 1 |
| Pei, X | 1 |
| Sirica, AE | 2 |
| Lai, GH | 2 |
| Endo, K | 1 |
| Zhang, Z | 2 |
| Yoon, BI | 1 |
3 other studies available for emodin and Cholangiocarcinoma
| Article | Year |
|---|---|
Identification of a prognosis-related ceRNA network in cholangiocarcinoma and potentially therapeutic molecules using a bioinformatic approach and molecular docking.
Topics: alpha-Tocopherol; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers, Tumor; Calcium-Binding | 2022 |
Cyclooxygenase-2 and ERBB-2 in cholangiocarcinoma: potential therapeutic targets.
Topics: Animals; Bile Duct Neoplasms; Cholangiocarcinoma; Emodin; Enzyme Inhibitors; Humans; Prostaglandin-E | 2002 |
Celecoxib acts in a cyclooxygenase-2-independent manner and in synergy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced Akt inactivation and increased activation of caspases-9 and -3.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, | 2003 |